Loading organizations...
ASGEN Pharmaceutical Co., Ltd. develops and manufactures crude drug-based medicines, primarily focusing on solutions for asthma and allergic diseases. The company employs its extensive knowledge in herbal medicine to produce a range of pharmaceutical products, including contract manufacturing services and the import of traditional Chinese medicine. Utilizing advanced facilities, ASGEN maintains rigorous quality control standards to ensure a stable supply of trusted products aimed at improving the Quality of Life for its users.
The company was founded in October 1925 by Minoru Mizuno, who established "Mizuno Pharmacy" and obtained a permit to manufacture asthma medicine. This foundational product was named "ASGEN" in 1927, derived from the German word "Asthma" and the Japanese word "Ashita" (tomorrow), reflecting the original vision of fostering a healthier future for patients. The organization officially became ASGEN Pharmaceutical Co., Ltd. in January 1968, building upon decades of expertise.
ASGEN serves patients with allergic conditions, as well as general consumers seeking products for health maintenance, illness prevention, and primary care. Its core mission centers on contributing to the "Improvement of the Quality of Life" for both patients and consumers. Looking forward, the company aims to integrate digital technologies, including AI, into its research, development, and production systems, ensuring continued high-quality contributions to global health and a better tomorrow for all.
Asgen has 1 tracked investment across 1 company. The latest tracked deal is $10.0M Series B in Karamba Security in December 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Dec 1, 2021 | Karamba Security | $10.0M Series B | Linh Pham | Biomatics Capital Partners, Illumina Ventures, NanoDimension, Paladin Capital Group, Rich Simoni, Fontinalis Partners, Glenrock, Liberty Mutual, Presidio Ventures, Samsung, YL Ventures |